Virtual / Reality

We have a carport and it’s a great place for visits most of the year. A dear friend from High School ordered a heater for us and had it delivered shortly after a chilly visit last Fall, and that has extended the carport visiting season. So grateful!

It’s very special to be able to meet with people in person, and this summer quite a few friends are coming to town and making time for carport visits. Yesterday a childhood friend (we used to play piano duets together) came from the Seattle area and her Mom (who still lives in the same home with the same phone number (which I and so many others still remember)) came to visit. Such a treat! It’s so good to see people in person, even from 6 feet apart outside. In my opinion, it’s better in person than at a distance. Better in reality than virtually, in my opinion.

Don’t get me wrong, virtually is good, and in some circumstances it can open doors and provide opportunities that would not otherwise be possible. This is one of the silver linings of COVID and don’t get me wrong, I am grateful. It’s so good to meet “face to face” virtually when it’s too challenging (for a potential variety of reasons) to really meet face to face. There are good reasons for both. There is a season for everything. So grateful for a variety of options.

This is one of the reasons I’m such a fan of and advocate for CRAFT, 3CTN’s framework to make clinical trials more accessible for Canadians living in remote and rural parts of our geographically huge country. So important! 

Here’s a short video about CRAFT with some great quotes from a few people which was made over a year ago. CRAFT has now been rolled out and is serving people at several locations.

Zoom and other similar platforms have enabled many of us to speak at international conferences and other events the past couple of years. I’ve spoken at so many virtually, and we recognize the upside of not having to travel and spend time away. This has been a good gift which has also been a real difference maker for many of us.

Speaking personally, these visual platforms have also transformed much of my patient research advocacy in other ways. I used to have so many phone call meetings prior to COVID, and some of them with quite a large number of people. Initially I hadn’t met all the researchers in person and I did not always recognize all the voices. Sometimes some of the people did not introduce themselves when they started speaking and it could be challenging to figure out which person (from which place) was speaking. It’s so much easier with platforms that can show faces and even list their names. So much easier to get to know people and be better able to contextualize their comments. So  much better for community building than a mere large group phone call. So grateful for this!

In recent months, many members of the lung cancer community and other friends have sent gift certificates for our family to order food in. It means so much to receive this support that comes with love and appreciation. One ordered pizza for us, several have brought food, and many friends including our church community has brought much food and sent food in various ways as well. It’s such a treat and very much appreciated. Twice people have sent fruit bouquets which are so delicious, and so many other yummy things have arrived at our door – too many to name, and received with tremendous appreciation whether sweet or savoury. Thank you!

I’m very grateful for local friends who have done things this week – again, too many to name – like offer to pick up a walker for me, or regularly walk our dog. The reality is that there are times when we need real physical, local support. So many people here in Ottawa have offered and/or given support when needed, for example, rides to appointments, picking up groceries etc. Where would we be without our local people?

As much as we appreciate the virtual reality, we recognize there are some things that obviously cannot be done from a distance. Even for those who are part of strong virtual support groups, it seems obvious that it’s important to make sure we are also cultivating relationships with people in our own geographic community. We never know when we might need local support.

Please let me say again that we are incredibly grateful for the reality of this local support as well as the support from a distance.

#love

#hope

#support

August 1 is World Lung Cancer Day. What is your cancer center doing to celebrate?

Clinical Trials, Vaccines and Hope

My hope factor increased today and I hope yours will as well! I got an update today that improved my world! Researchers are working on bringing a whole lot of good our way, and I can’t wait to tell you about it!

Over a year ago I participated in the American Association for Cancer Research Scientist <–> Survivor Program. Today through Wednesday, the AACR is putting on a Virtual Meeting on COVID-19 and Cancer. I really want to tell you about two virtual sessions I attended today: one about clinical trials, and the other about vaccine development.

I was very excited to hear the clinical trials forum speakers talk about how their clinical trial communities have reacted to world changes brought on by COVID-19. I’ve heard some people express fear that clinical trials might take a back seat to COVID-19, but there’s a lot more good reason for hope and optimism! Speakers in today’s forum described how they had worked creatively to overcome challenges, leverage tools and technologies, while focusing on patient safety and accuracy of data.

This pandemic has shifted the focus of many clinical trials to be more patient-centric. Researchers and doctors are finding that telehealth can work really well, and many tests are being done closer to home, sometimes even at home, thanks to the quick pivoting of regulators and investigators which makes clinical trials work effectively in these different times.

Decentralizing clinical trials improves and expands access. Clinical trials accrual is increasing, as is diversity. Underserved populations are being recruited, getting improved access to clinical trials. This is important good news!

[It’s something we have been working on in Canada, too. 3CTN recently announced two new initiatives to increase access to cancer clinical trials, with nearly $1 million in funding from the Canadian Partnership Against Cancer. Great news! #AccessMatters]

Leaders in clinical trial research are not just reacting quickly to unusual times, they are also taking advantage of what they are learning to reimagine and work for a future with better, faster, simpler and cheaper ways of making innovative new life-extending therapies available to people affected by cancer.

The vaccine development symposium was fascinating, exciting and inspiring! Researchers are working at breakneck speed, crushing previous vaccine development records and producing hopeful results. Researchers made it clear that they are building on earlier work of MERS, SARS and other researchers who laid the framework upon which current work is built. Pandemic preparedness matters. #ResearchMatters

So grateful for front line workers, researchers and all who work to make research happen. Thank you.

www.aacr.org #AACRCOVID #hope

More details about the events below these pictures from the awesome AACR Annual Meeting 2019 #AACR19 …

FORUM 1: REGULATORY AND OPERATIONAL IMPLICATIONS OF CANCER CLINICAL TRIAL CHANGES DURING COVID-19
1:05-2:05 P.M.
MODERATOR: KEITH T. FLAHERTY, MASSACHUSETTS GENERAL HOSPITAL BOSTON, MASSACHUSETTS

José Baselga, AstraZeneca, Gaithersburg, Maryland
James Doroshow, National Cancer Institute, Bethesda, Maryland
Kristen M. Hege, Bristol-Myers Squibb, San Francisco, California
Paul G. Kluetz, U.S. Food and Drug Administration, Silver Spring, Maryland
Patricia M. LoRusso, Yale University School of Medicine, New Haven, Connecticut
Caroline Robert, INSERM U981 (Gustave Roussy), Villejuif, France

SYMPOSIUM 3: COVID-19 VACCINE DEVELOPMENT
2:20-4:20 P.M.

Introduction
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

Rapid SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness
Kizzmekia S. Corbett, National Institutes of Allergy and Infectious Diseases (NIAID), Bethesda Maryland

Pan-HLA prediction of SARS-CoV-2 epitopes*
Katie M. Campbell, University of California, Los Angeles, California

Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes*
Asaf Poran, BioNTech US, Cambridge, Massachusetts

A computational approach to identify a possible SARS-CoV-2 vaccine from receptor binding domain peptide sequence on spike glycoproteins*
Majid Al-Zahrani, King Abdulaziz University, Jeddah, Saudi Arabia

Synthetic DNA for EID outbreaks including SARS-CoV2
David Weiner, The Wistar Institute, Philadelphia, Pennsylvania

Closing Remarks / Discussion

E. John Wherry

*Short talks from proffered papers